Dong-A ST Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1932-01-01

Employees: 1.6K

Market Cap: -

Website: http://www.donga-st.com

Clinical Trials

The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients with Acquired Lumbar Spinal Stenosis

Recruiting

Conditions: Lumbar Spinal Stenosis

First Posted Date: 2024-10-23

Last Posted Date: 2024-10-28

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 243

Registration Number: NCT06654856

Locations: 🇰🇷
VHS Medical Center, Seoul, Korea, Republic of

Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: DA-5221_01
Drug: DA-5221_01-R1 + DA-5221_01-R2

First Posted Date: 2024-09-27

Last Posted Date: 2024-09-27

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 44

Registration Number: NCT06616883

Locations: 🇰🇷
Bumin Hospital, Seoul, South Korea, Korea, Republic of

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: DA-7503 Single dose
Drug: Placebo Single dose
Drug: DA-7503 Multiple dose
Drug: Placebo Multiple dose

First Posted Date: 2024-04-30

Last Posted Date: 2024-04-30

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT06391827

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Not yet recruiting

Conditions: Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: DA-4505
Drug: DA-4505 + Pembrolizumab

First Posted Date: 2024-03-05

Last Posted Date: 2024-03-05

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 125

Registration Number: NCT06293651

Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Phase 3

Not yet recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: DA5221-T1
Drug: Placebo
Drug: DA5221-T2
Drug: DA5221-B1
Drug: DA5221-B2

First Posted Date: 2024-03-04

Last Posted Date: 2024-03-04

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 162

Registration Number: NCT06290349

Locations: 🇰🇷
Severance Hospital, Yonsei University college of Medicine, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

Phase 3

Recruiting

Conditions: Gastritis Chronic
Gastritis Acute

Interventions: Drug: DA-5219
Drug: Stillen® Tab
Drug: Stillen® Tab Placebo
Drug: DA-5219 Placebo

First Posted Date: 2023-11-30

Last Posted Date: 2024-04-04

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 452

Registration Number: NCT06151210

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: DA-8010 5mg
Drug: Paroxetine 20mg
Drug: Mirabegron 50mg

First Posted Date: 2023-08-15

Last Posted Date: 2024-01-25

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT05992428

Locations: 🇰🇷
Seoul National University Hospital, Soeul, Korea, Republic of

Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: DA-8010 5mg
Drug: Clarithromycin 500mg
Drug: Rifampicin 600mg

First Posted Date: 2023-08-14

Last Posted Date: 2024-01-25

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT05991401

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Phase 4

Completed

Conditions: Hepatitis B

Interventions: Drug: DA-2803
Drug: DA-2803-R
Drug: Placebo of DA-2803-R
Drug: Placebo of DA-2803

First Posted Date: 2023-07-24

Last Posted Date: 2024-10-23

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05957380

Locations: 🇰🇷
The Catholic University of Korea, Seoul, Seoul, Korea, Republic of

Clinical Trial of DA-5212 in Patients with Functional Dyspepsia

Phase 3

Completed

Conditions: Functional Dyspepsia

Interventions: Drug: DA-5212
Drug: DA-5212-R

First Posted Date: 2023-05-06

Last Posted Date: 2024-12-13

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 384

Registration Number: NCT05842408

Locations: 🇰🇷
Wonkwang University Hospital, Iksan, Muwangro 895, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy